Cowen slashes price target on Zymergen Inc. [ZY] – find out why.

Related

Zymergen Inc. [NASDAQ: ZY] stock went on an upward path that rose over 8.48% on Wednesday, amounting to a one-week price increase of more than 13.02%. The company report on July 25, 2022 that Ginkgo to Acquire Zymergen.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Acquisition is expected to accelerate the development of Ginkgo’s innovative horizontal synthetic biology platform.

Expect integration of Zymergen’s complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo’s platform for its diverse customer base and enable new growth opportunities across many end markets.

Over the last 12 months, ZY stock dropped by -92.16%. The one-year Zymergen Inc. stock forecast points to a potential upside of 19.0. The average equity rating for ZY stock is currently 3.30, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $270.70 million, with 103.11 million shares outstanding and 95.21 million shares in the current float. Compared to the average trading volume of 1.62M shares, ZY stock reached a trading volume of 3953930 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Zymergen Inc. [ZY]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ZY shares is $3.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ZY stock is a recommendation set at 3.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cowen have made an estimate for Zymergen Inc. shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on March 02, 2022. The new note on the price target was released on January 12, 2022, representing the official price target for Zymergen Inc. stock.

The Average True Range (ATR) for Zymergen Inc. is set at 0.18, with the Price to Sales ratio for ZY stock in the period of the last 12 months amounting to 15.21. The Price to Book ratio for the last quarter was 0.73, with the Price to Cash per share for the same quarter was set at 3.03.

ZY Stock Performance Analysis:

Zymergen Inc. [ZY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.02. With this latest performance, ZY shares gained by 77.37% in over the last four-week period, additionally sinking by -50.10% over the last 6 months – not to mention a drop of -92.16% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ZY stock in for the last two-week period is set at 70.85, with the RSI for the last a single of trading hit 74.93, and the three-weeks RSI is set at 65.63 for Zymergen Inc. [ZY]. The present Moving Average for the last 50 days of trading for this stock 1.59, while it was recorded at 2.23 for the last single week of trading, and 4.73 for the last 200 days.

Insight into Zymergen Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Zymergen Inc. [ZY] shares currently have an operating margin of -1943.13 and a Gross Margin at -440.02. Zymergen Inc.’s Net Margin is presently recorded at -2160.81.

Zymergen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.90 and a Current Ratio set at 4.00.

ZY Stock EPS

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ZY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Zymergen Inc. go to 13.80%.

Zymergen Inc. [ZY] Insider Position Details

There are presently around $161 million, or 69.70% of ZY stock, in the hands of institutional investors. The top three institutional holders of ZY stocks are: SB INVESTMENT ADVISERS (UK) LTD with ownership of 26,614,219, which is approximately 0% of the company’s market cap and around 4.20% of the total institutional ownership; BLACKROCK INC., holding 4,192,794 shares of the stock with an approximate value of $10.19 million in ZY stocks shares; and JPMORGAN CHASE & CO, currently with $10.13 million in ZY stock with ownership of nearly 17.023% of the company’s market capitalization.

Positions in Zymergen Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 45 institutional holders increased their position in Zymergen Inc. [NASDAQ:ZY] by around 7,487,211 shares. Additionally, 35 investors decreased positions by around 4,964,203 shares, while 24 investors held positions by with 53,846,452 shares. The mentioned changes placed institutional holdings at 66,297,866 shares, according to the latest SEC report filing. ZY stock had 14 new institutional investments in for a total of 3,235,070 shares, while 12 institutional investors sold positions of 1,141,940 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]